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Background: Reduced RHOA signalling has been shown to increase the growth/metastatic potential of colorectal tumours.
However, the mechanisms of inactivation of RHOA signalling in colon cancer have not been characterised.
Methods: A panel of colorectal cancer cell lines and large cohorts of primary tumours were used to investigate the expression and
activity of RHOA, as well as the presence of RHOA mutations/deletions and promoter methylation affecting RHOA. Changes in
RHOA expression were assessed by western blotting and qPCR after modulation of microRNAs, SMAD4 and c-MYC.
Results: We show here that RHOA point mutations and promoter hypermethylation do not significantly contribute to the large
variability of RHOA expression observed among colorectal tumours. However, RHOA copy number loss was observed in 16% of
colorectal tumours and this was associated with reduced RHOA expression. Moreover, we show that miR-200a/b/429
downregulates RHOA in colorectal cancer cells. In addition, we found that TGF-b/SMAD4 upregulates the RHOA promoter.
Conversely, RHOA expression is transcriptionally downregulated by canonical Wnt signalling through the Wnt target gene c-MYC
that interferes with the binding of SP1 to the RHOA promoter in colon cancer cells.
Conclusions: We demonstrate a complex pattern of inactivation of the tumour suppressor gene RHOA in colon cancer cells
through genetic, transcriptional and post-transcriptional mechanisms.
The small GTPases of the RHO family, including RHOA, RAC and
CDC42, are molecular switches that cycle between a GTP-bound
active form and a GDP inactive form, and participate in key
aspects of the oncogenic process such as proliferation, polarisation,
apoptosis, adhesion, migration, invasion and metastasis (Itoh et al,
1999; Sahai and Marshall, 2002). Activation of RHO proteins is
most commonly reported to be oncogenic and has been shown to
promote transformation of different cell types (Sahai and Marshall,
2002). However, we have recently shown that RHOA (Ras
homologue family member A) has tumour suppressor activity in
colorectal cancer and the loss of this GTPase significantly
contributes to tumour progression and metastasis, largely through
the activation of canonical Wnt signalling (Rodrigues et al, 2014)
and low RHOA expression is associated with poor patient
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prognosis (Arango et al, 2005). Tumour suppressor genes are
inactivated during the tumourigenic process by a variety of
mechanisms, including genetic and epigenetic alterations, over-
expression of regulatory microRNAs or direct transcriptional
silencing of the promoter, and the molecular mechanisms
regulating the loss of RHOA expression and activity in colorectal
cancer cells are not well understood.
Large exome/genome sequencing studies of colorectal tumours
have demonstrated low mutation frequency of RHOA in colorectal
tumours (Cancer Genome Atlas Network, 2012; Seshagiri et al,
2012). Consistent with the oncogenic activity of RHOA in most
tumour types investigated, reduced promoter methylation levels
associated with RHOA overexpression have been reported in
different tumour types (Braga et al, 2015). In addition, RHOA levels
have been shown to be regulated by miR-155, miR-340 and miR-
200a/b/429 in endothelial cells (Bijkerk et al, 2012), melanocytes
(Jian et al, 2014) and hepatocellular carcinoma (Wong et al, 2015),
respectively. However, the regulation of RHOA by miRNAs in
colorectal cancer cells has not been investigated in detail.
Activation of canonical Wnt signalling and inactivation of TGF-
b signalling play key roles in the initiation and progression of
colorectal tumours (Mishra et al, 2005). Both pathways convey
extracellular signals from the membrane to the nucleus, regulating
the transcription of multiple genes that participate in tumour
growth and metastasis. Canonical Wnt signalling is a master
regulator of proliferation and differentiation in normal intestinal
epithelial cells and colon cancer cells (Mishra et al, 2005). Almost
80–90% of colorectal tumours have hyperactive Wnt signalling,
most frequently because of inactivating mutations in APC that
leads to the nuclear accumulation of b-catenin and the transcrip-
tional activation of multiple targets, such as c-MYC and Cyclin D1
(Bienz and Clevers, 2000). On the other hand, TGF/SMAD
signalling, an important regulator of cell growth and differentia-
tion, is initiated by TGF-b superfamily ligands binding to type II
TGF-b receptors, leading to the activation of SMAD intracellular
mediators that translocate then into the nucleus, where they
regulate transcription (Moustakas et al, 2001). TGF-b signalling is
frequently silenced in colorectal tumours through different
mechanisms, such as mutations in TGFBR2 or SMAD4 (Parsons
et al, 1995; Eppert et al, 1996; Alazzouzi et al, 2005).
In this study, we found that multiple mechanisms contribute to
the inactivation of RHOA signalling in colorectal cancer cells. The
loss of the chromosomal region containing RHOA (3p21) was
associated with reduced expression of this GTPase. Moreover, miR-
200a/b/429 was found to inhibit the expression of RHOA in
colorectal cancer cells. Importantly, we also demonstrate that
transcriptional downregulation of RHOA through the TGF-b and
Wnt signalling pathways is an important mechanism contributing
to the inactivation of RHOA signalling.
MATERIALS AND METHODS
Cell lines and plasmids. The LS174T/W4, LS174T/dnTCF4,
LS174T/sibCAT, SW480/ADH, HCT8/S11 and HCT116-
SMAD4-/- were kindly provided by other researchers, as detailed
in the Supplementary Methods. Other cell lines used in this study
(LIM2405, HCT116, RKO, SK-CO-1, SW837 and HEK293T) were
obtained from the American Type Culture Collection (ATCC,
Manassas, VA, USA). All plasmids used are described in the
Supplementary Methods.
Luciferase reporter assays. Renilla luciferase (pRL-TK; Promega,
Madison, WI, USA) was used as a control for transfection
efficiency in luciferase reporter assays using the Dual-Luciferase
Assay Kit (Promega).
Western blot and RHOA activity determination. The GTP-
bound RHOA levels and western blotting were carried out as
previously described (Rodrigues et al, 2014). The antibodies used
are described in the Supplementary Methods.
CpG island methylation assays and microarray analysis. The
DNA methylation status in the 1145 bp CpG island located in the
promoter of RHOA was assessed on colon cancer cell lines by
methylation-specific PCR (MSP-PCR), bisulphite sequencing and
HumanMethylation27 Beadchips (Illumina, San Diego, CA, USA).
Relative mRNA levels were determined by microarray analysis
(HG-U133 Plus 2.0 chips; Affymetrix, Santa Clara, CA, USA) as
previously reported (Bazzocco et al, 2015).
Animal experiments. C57BL/6J-ApcMin/J mice were obtained
from The Jackson Laboratory (Stock No: 002020, Bar Harbor,
ME, USA). All animal experiments were carried out under
protocols approved by the Vall d’Hebron Ethical Committee for
Animal Experimentation.
Immunohistochemistry and quantitative RT–PCR. The expres-
sion of RHOA and SMAD4 in Dukes’ C colorectal tumours have
been reported before (Alazzouzi et al, 2005; Arango et al, 2005).
Total RNA was reverse transcribed and relative levels of the
indicated genes were assessed by real-time PCR using SYBR Green
Master Mix (Applied Biosystems, Foster City, CA, USA). All
primers used are detailed in the Supplementary Methods.
ChIP assay. The RKO cells were treated for 24 h with 1mM JQ1 (or
vehicle DMSO) and fixed with formaldehyde (Thermo Scientific,
Waltham, MA, USA). Cell pellets were resuspended in nuclei lysis
buffer and sonicated with a Bioruptor instrument (Diagenode,
Liege, Belgium). Then, 200 mg of the cleared supernatant was
immunoprecipitated with anti-SP1 antibody (Millipore 07-645,
Burlington, MA, USA) or unspecific rabbit IgG. After washing,
samples were treated with proteinase K and DNA recovered
(Qiagen PCR product purification kit, Hilden, Germany). Relative
levels of RHOA, p21 and a negative control (gene desert in
chromosome 12) were quantified by real-time PCR as detailed in
the Supplementary Methods.
RESULTS
RHOA expression in colorectal tumours. The expression of the
small GTPase RHOA is frequently downregulated (Supplementary
Figure 1A) and contributes significantly to the progression of
colorectal cancer (Rodrigues et al, 2014). To investigate the
mechanisms regulating the expression of RHOA in colorectal
cancer cells, we first assessed the RHOA mRNA levels in a panel of
59 colorectal cancer cell lines using RNA sequencing (Mouradov
et al, 2014). Significant variability in RHOA expression was
observed (Supplementary Figure 2A and Supplementary Table 1)
and the mRNA expression levels in a subset of 34 of these cell lines
was confirmed by microarray analysis (Bazzocco et al, 2015)
(Supplementary Figure 2B; Pearson’s r¼ 0.52 and P¼ 0.0018). The
levels of RHOA protein were then assessed in a subset of 18
colon cancer cell lines using western blot analysis, confirming a
wide range of RHOA expression in colorectal cancer cell lines
also at the protein level (Supplementary Figure 2C and
Supplementary Table 1). The range of expression in primary
colorectal tumours and cell line models was comparable
(Supplementary Figure 1B–G). A significant correlation between
the levels of RHOA mRNA and protein was observed in colorectal
cancer cells (Supplementary Figure 2D; Pearson’s r¼ 0.6 and
P¼ 0.018). We then used a rhotekin pull-down assay to assess the
levels of active RHOA in 18 colorectal cancer cell lines
(Supplementary Figure 2C) and observed a significant correlation
between total RHOA expression and GTP-bound active RHOA
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(Supplementary Figure 1E and Supplementary Table 1; Pearson’s
r¼ 0.53 and P¼ 0.025).
Genetic inactivation of RHOA in colorectal tumours. Previous
studies have shown that RHOA is not frequently mutated in
colorectal tumours (Arango et al, 2005). Meta-analysis of RHOA
mutation frequencies in 983 colorectal primary tumours (Cancer
Genome Atlas Network, 2012; Seshagiri et al, 2012; Brannon et al,
2014; Giannakis et al, 2016) showed that only 1.0% (10 out of 983)
of colorectal tumours have RHOA mutations and that these are
randomly distributed throughout its coding sequence
(Supplementary Figure 3). Therefore, the low incidence of
mutations observed in RHOA cannot explain the large variability
of RHOA levels observed in colorectal tumours. However, RHOA
copy number losses in chromosome 3p21 affecting RHOA were
observed in 16% (60 of 376) of colorectal tumours from The
Cancer Genome Atlas (TCGA) initiative (Cancer Genome Atlas
Network, 2012) and this was associated with reduced RHOA
expression (Figure 1A and Supplementary Table 2). In good
agreement, we observed RHOA losses in 13.8% (4 out of 30) of
colorectal cancer cell lines, and this was associated with
significantly lower RHOA mRNA expression (Figure 1B and
Supplementary Table 1). Therefore, deletions of chromosome 3p21
affecting RHOA could account for the reduced levels of RHOA
observed in a subset of colorectal tumours.
Epigenetic inactivation of RHOA in colorectal tumours. Hyper-
methylation of promoter CpG islands in the promoter region of
tumour suppressor genes is an important mechanism silencing the
expression of genes with tumour suppressor activity (Corte´ et al,
2012). Because the proximal promoter region of RHOA contains a
CpG island spanning41400 bp flanking its transcription start site
(Supplementary Figure 4), we investigated whether methylation of
this region was associated with loss of RHOA expression in
colorectal tumours by determining the levels of RHOA promoter
methylation in 30 colon cancer cell lines and using publicly
available data from 370 primary colorectal tumours (Cancer
Genome Atlas Network, 2012) (Supplementary Tables 1 and 2).
Quantification of the levels of methylation of 16 CpG dinucleotides
in the promoter of RHOA using HumanMethylation450 BeadChip
arrays (Illumina) revealed low levels of methylation in colorectal
tumours (Supplementary Figure 5A), and this finding was
independently confirmed in colorectal cancer cell lines using
either bisulphite sequencing of a region of 254 bp containing 15
CpGs flanking the RHOA transcription start site (Figure 1C and
Supplementary Figure 6A) or methylation-specific PCR of the
same region (Supplementary Figure 6B). Furthermore, no associa-
tions were observed between the levels of methylation and
expression of RHOA in colorectal cancer cell lines and primary
tumours (Figure 1D and E and Supplementary Figure 5B). These
results indicate that RHOA promoter methylation does not
regulate RHOA expression in colorectal tumours.
Post-transcriptional regulation of RHOA by miRNAs in color-
ectal tumours. Previous studies in other tumour types have
demonstrated regulation of RHOA expression by microRNAs
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Figure 1. Genetic and epigenetic alterations of RHOA in colorectal tumours. (A and B) Scatter dot plot (and mean±s.e.m.) showing RHOAmRNA
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(Wong et al, 2015). To investigate this in colorectal cancer cells, we
used a cohort of 195 primary colorectal tumours where the levels of
mRNA and miRNA expression were determined by RNAseq
(Cancer Genome Atlas Network, 2012) (Supplementary Table 2).
This analysis identified 47 miRNAs whose expression was also
significantly negatively correlated with RHOA expression
(Supplementary Table 3). In silico analysis predicted evolutionarily
conserved binding sites for 14 of these miRNAs (Supplementary
Table 3). Importantly, the expression of 12 of these 14 miRNAs
was significantly elevated in colorectal tumours compared with the
normal colonic mucosa (Supplementary Table 3), suggesting that
different miRNAs may contribute to the downregulation of RHOA
observed in colorectal tumours.
Of these 14 miRNAs, miR-200b and miR-429, which are located
in the miR-200a/b/429 cluster on chromosome 1 and are
transcribed together, showed the highest homology to RHOA
(TargetScan), and are highly conserved from Xenopus to humans
(Betel et al, 2010). To investigate the possible regulation of RHOA
by miR-200a/b/429, we transiently co-transfected the miR-200a/b/
429 genomic cluster along with a reporter construct expressing
luciferase fused to the RHOA 3’-UTR that was either wild type or
mutant for the putative miR-200a/b/429 binding site. LIM2405
colon cancer cells were used for these experiments as they express
low endogenous levels of miR-200a/b/429 (Supplementary
Figure 7A). Overexpression of miR-200a/b/429 significantly
reduced luciferase reporter activity in the cells transfected with
the wild-type RHOA 3’-UTR construct compared with the mutant
construct (Figure 2A), providing evidence of direct regulation of
RHOA expression by these microRNAs. Moreover, stable over-
expression of the miR-200a/b/429 cluster in LIM2405 cells
significantly reduced the endogenous mRNA levels of RHOA, as
well as ZEB1, a known target of miR-200a/b/429 (Hur et al, 2013)
(Figure 2B–D and Supplementary Figure 7B). Collectively, these
results demonstrate that the miR-200a/b/429 cluster significantly
contributes to the downregulation of RHOA observed in colorectal
cancer cells. Moreover, we identified additional microRNAs that
could further modulate the levels of RHOA in colorectal cancer
cells (Supplementary Table 3).
Transcriptional regulation of RHOA in colorectal tumours.
Regulation of the activity of the promoter is a key mechanism
controlling gene expression. To assess the extent to which RHOA
expression is regulated at the transcriptional level we utilised a
reporter construct containing the 2 kb promoter region immedi-
ately upstream of the RHOA transcription start site driving the
expression of luciferase (Chan et al, 2010). Transient transfection
of this reporter construct in 14 colon cancer cell lines revealed
significantly higher RHOA promoter activity in cell lines with high
endogenous RHOA mRNA expression (Figure 3A), suggesting that
regulation of the transcriptional activity of the RHOA promoter is
an important mechanism determining the levels of RHOA
expression in colorectal cancer cells.
Detailed in silico analysis of the proximal RHOA promoter
identified the presence of potential binding sites for at least 57
transcription factors (Supplementary Table 4). To identify
physiological regulators of RHOA transcription in colon cancer
cells, we correlated the levels of RHOA mRNA with the expression
of these transcription factors assessed by RNAseq in a cohort of
244 primary colorectal tumours (TCGA; Supplementary Table 2)
(Cancer Genome Atlas Network, 2012). Of the 57 transcription
factors with putative binding motifs in the RHOA promoter, the
expression of 44 (77.2%) of them was significantly correlated with
the expression of RHOA (Supplementary Table 4), suggesting that
they may directly regulate RHOA expression in colorectal tumours.
Notably, these included binding sites for SMAD4 and c-MYC that
are key effectors of the TGF-b and Wnt signalling, two of the most
commonly deregulated pathways in colorectal cancer.
Transcriptional regulation of RHOA by TGF-b signalling in
colorectal cancer cells. SMAD4 is a transcription factor regulated
by the TGF-b pathway and has important tumour suppressor
activity in colorectal tumours (Howe et al, 1998; Alazzouzi et al,
2005). SMAD4 mRNA levels showed a significant positive
correlation with RHOA mRNA levels in 244 primary colorectal
tumours (Supplementary Tables 2 and 4, Figure 3B; Pearson’s
r¼ 0.47; P¼ 7.97 10-15). Moreover, quantification of the levels of
RHOA (Arango et al, 2005) and SMAD4 (Alazzouzi et al, 2005;
Alhopuro et al, 2005) protein by immunohistochemistry in a tissue
microarray containing triplicate samples of 162 primary colorectal
tumours confirmed a significant association between RHOA and
SMAD4 expression (Pearson’s r¼ 0.48; P¼ 7.8 10-11; Figure 3C),
further suggesting an important role for SMAD4 in the regulation
of RHOA expression in these tumours.
To investigate whether TGF-b signalling functionally regulates
the expression of RHOA, SKCO1 colon cancer cells, which have a
functional TGF-b signalling pathway (Brunen et al, 2013), were
stimulated with TGF-b1. As expected, TGF-b1 resulted in
increased SMAD4 transactivation activity (Figure 3D). In addition,
TGF-b1 enhanced RHOA promoter activity (Figure 3D) and
elevated RHOA mRNA and protein expression (Figure 3E and F).
SMAD4 has previously been shown to bind to the RHOA promoter
in human embryonic stem cells (Tsankov et al, 2015). Importantly,
targeted inactivation of SMAD4 in HCT116 and SKCO1 colon
cancer cells resulted in reduced RHOA mRNA levels (Figure 3G
and H). These results collectively indicate that RHOA is
transcriptional target of SMAD4 in colon cancer cells.
Transcriptional regulation of RHOA by Wnt signalling in
colorectal cancer cells. Canonical Wnt signalling is a master
regulator of proliferation and differentiation of both normal intestinal
epithelial cells and colon cancer cells (MacDonald et al, 2009). We
therefore investigated whether Wnt/b-catenin also regulates RHOA
expression using LS174T cells where TCF4/b-catenin signalling can
be inactivated by doxycycline-dependent overexpression of a
dominant negative form of TCF4 (LS174T-dnTCF4) or an shRNA
targeting b-catenin (LS174T-shBCAT) (Van de Wetering et al, 2002).
As expected, doxycycline treatment of both LS174T-dnTCF4 and
LS174T-shBCAT cells significantly reduced the transcriptional
activity of TCF4/b-catenin as assessed using a luciferase reporter
construct (Supplementary Figure 8A and B). Importantly, this
decrease in TCF4/b-catenin activity was associated with increased
promoter activity (Figure 4A), mRNA expression (Figure 4B) and
protein levels and activity (Figure 4C) of RHOA. The transcriptional
regulation of RHOA by TCF4/b-catenin was further confirmed by
transient transfection of dominant negative TCF4 in four additional
colon cancer cell lines (SW837, HCT8/S11, SW480/ADH and
LS174T/W4; Figure 4D and Supplementary Figure 8C).
In addition, we used a mouse model of intestinal tumourigenesis
carrying heterozygous germline Apc mutations (Apcmin model)
(Moser et al, 1990) to assess the effects of Wnt pathway activation on
RhoA levels in vivo. Heterozygous Apc mutations in normal
intestinal epithelial cells did not affect the levels of RHOA protein
(Figure 4E and F and Supplementary Figure 8D–F). However, the
sporadic loss of the wild-type allele in these cells results in
hyperactivation of Wnt/b-catenin and the formation of intestinal
tumours (Luongo et al, 1994; Sansom et al, 2004) and reduced RhoA
expression was observed in the intestinal tumours of Apcmin mice
compared with the normal intestinal epithelium of either wild-type
or Apcmin mice (Figure 4E and F and Supplementary Figure 8D–F).
Collectively, these results indicate that RHOA expression is
repressed by aberrant Wnt signalling in colorectal cancer cells.
Transcriptional regulation of RHOA by c-MYC in colorectal
cancer cells. Because the promoter region of RHOA used for these
experiments does not contain binding sites for the TCF4/b-catenin
transcriptional complex, the effects of Wnt signalling on the
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RHOA promoter are likely to be indirect. The c-MYC is an
important transcriptional target of TCF4/b-catenin and has been
reported to regulate the expression of RHOA in prostate and breast
cancer cells (Chan et al, 2010). Moreover, c-MYC and RHOA
mRNA expression were negatively correlated in a cohort of 244
primary colorectal tumours (Supplementary Table 4).
We have previously shown that RHOA negatively regulates
Wnt/c-MYC signalling in the colon cancer cells lines SW480/ADH,
HCT8/S11, LS174T/W4 and SW837. To investigate the possible
reciprocal regulation of the RHOA promoter by c-MYC in colon
cancer cells, we assessed the effects of ectopic expression of c-MYC
in the same cell lines as well as in HEK293T human embryonic
kidney cells. c-MYC can enhance the promoter activity of multiple
targets, such as CDK4, through its binding to E-boxes or inhibit the
promoter activity of other target genes, such as p21CIP1/WAF1
through alternative mechanisms (Seoane et al, 2002). As expected,
overexpression of c-MYC led to a significant activation of the
CDK4 promoter and reduced the activity of the p21CIP1/WAF1
promoter (Figure 5A and B). In addition, and consistent with
previous reports (Chan et al, 2010), c-MYC overexpression in
HEK293T cells led to a significant increase in the transcription of
RHOA (Figure 5C). However, ectopic expression of c-MYC in four
different colon cancer cell lines (SW837, HCT8/S11, SW480/ADH
and LS174T/W4) resulted in decreased RHOA promoter activity
(Figure 5C).
To further confirm the regulation of RHOA expression by
c-MYC, we downregulated c-MYC levels either using c-MYC-
specific shRNA (Figure 5D and E) or treatment with the BET
bromodomain inhibitor JQ1 (Figure 5F and G) that has previously
been shown to reduce the expression of c-MYC (Delmore et al,
2011; To¨gel et al, 2016). Transient shMYC transfection resulted in
increased activity of the RHOA promoter in all four colon cancer
cell lines (Figure 5E). In addition, JQ1 treatment led to increased
mRNA and protein levels of RHOA as well as p21CIP1/WAF1 that
was used as a positive control (Cheng et al, 2013) (Figure 5F and
G). Collectively, these results demonstrate that c-MYC negatively
regulates the activity of the promoter of RHOA and leads to
reduced RHOA mRNA expression in colorectal cancer cells.
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c-MYC represses the RHOA promoter through its interactions
with SP1. c-MYC has been shown to repress the promoter
activity of target genes such as USF, C/EBPa or albumin through
its binding to initiator elements (Li et al, 1994). However, detailed
in silico analysis of the RHOA promoter did not identify
the presence of any consensus initiator elements. Alternatively,
c-MYC can repress the expression of some genes, such as
p21CIP1/WAF1, through the sequestration of the SP1/SP3 complex
(Gartel et al, 2001). Similar to the p21CIP1/WAF1 promoter, the
proximal promoter of RHOA contains several SP1 binding
sites (Figure 6A), and the levels of SP1 were significantly
correlated with the expression of RHOA in a series of 244 primary
colorectal tumours (Supplementary Tables 2 and 4; Pearson’s
r¼ 0.37; P¼ 5.8 10 9). A chromatin immunoprecipitation
(ChIP) assay demonstrated a significant enrichment in SP1-bound
DNA fragments spanning the RHOA promoter region in
untreated colon cancer cells compared with negative controls
(compare blue bars with (DMSO IgG) and without (DMSO SP1)
stripes for the RHOA promoter in Figure 6D), demonstrating SP1
binding to the RHOA promoter and further suggesting that SP1 is
important for RHOA transcription. Treatment with the SP1
inhibitor mithramycin resulted in a significant reduction of the
promoter activity and the expression of RHOA, as well as the
positive control p21CIP1/WAF1 (Figure 6B and C), further indicating
that SP1 transactivation is important to sustain RHOA expression
in colon cancer cells.
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To investigate whether c-MYC downregulates the expression of
RHOA by interfering with the capacity of SP1 to activate RHOA
transcription, we assessed possible changes in the levels of SP1
bound to the RHOA promoter following c-MYC downregulation
with JQ1. As a control (Gartel et al, 2001), we showed increased
SP1 binding to the p21CIP1/WAF1 promoter after c-MYC down-
regulation with JQ1 treatment using a ChIP assay (compare blue
(DMSO SP1) and green (JQ1 SP1) bars without stripes for the p21
promoter in Figure 6D). Importantly, reduced c-MYC levels after
JQ1 treatment resulted in a significant increase in SP1 bound to the
RHOA promoter (compare blue (DMSO SP1) and green (JQ1 SP1)
bars without stripes for the RHOA promoter in Figure 6D),
consistent with the notion that c-MYC downregulates RHOA levels
in colon cancer cells by reducing SP1 binding to the RHOA
proximal promoter.
DISCUSSION
RHOA is a small GTPase that in normal epithelial cells functions
as an important regulator of cytoskeleton structure, differentiation,
polarisation, cell adhesion and motility, and is activated in most
tumour types where it has been studied, mostly through its
overexpression (Itoh et al, 1999; Sahai and Marshall, 2002). In
contrast, we have previously shown that RHOA expression is
frequently lost or reduced in colorectal tumours and that low levels
of expression are associated with poor patient prognosis (Arango
et al, 2005), probably because of context-dependent differences in
RHOA signalling. Moreover, we have recently reported that the
loss of RHOA is an important driver of colorectal cancer
progression and metastasis (Rodrigues et al, 2014). However, the
underlying molecular mechanisms responsible for RHOA inactiva-
tion in colorectal tumours have not been previously investigated.
Here, we have carried out a comprehensive analysis of the possible
mechanisms downregulating RHOA activity in colorectal tumours,
and found that RHOA signalling is regulated by multiple
mechanisms that result in a significant reduction of RHOA
expression and activity in a high proportion of these tumours.
The RHO GTPases function as molecular switches that cycle
between a GTP-bound active state and a GDP-bound inactive state.
Here we found that although the levels of active RHOA-GTP are
known to be regulated by GEF and GAP proteins (Sahai and
Marshall, 2002), in colon cancer cells, the promoter activity as well as
the levels of RHOA mRNA and protein are significantly correlated
with the levels of GTP-bound active RHOA, as determined by a pull-
down assay based on the Rho binding domain (RBD) of the Rho
effector Rhotekin. These data indicate that RHOA signalling is
determined to a large extent by the transcriptional activity of the
RHOA promoter, although other layers of regulation further fine-
tune RHOA activity on colorectal tumours.
Whereas frequent recurrent RHOA mutations have been
reported in subtypes of T-cell leukaemia/lymphoma (Palomero
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et al, 2014) and gastric tumours (Zhou et al, 2014), RHOA
mutations are not frequent (1.0%; 10 out of 983) in colorectal
tumours, indicating that this is not a common mechanism
regulating RHOA signalling in this tumour type. However, RHOA
is located on the short arm of chromosome 3 (3p21.3), a region
frequently deleted in colorectal tumours (Mehus et al, 1999) and
that is known to contain several candidate tumour suppressor
genes, including NPRL2 (Yogurtcu et al, 2012) and RASSF1
(Fernandes et al, 2013). Here we show that copy number losses in
3p21.3 are associated with a significant reduction in RHOA
expression, suggesting that these deletions could target RHOA
among other genes in this region.
We show here that despite the presence of a dense CpG island
in the promoter of RHOA, uniformly low levels of methylation
were observed in this region in primary colorectal tumours and
cell lines, and no associations were observed with RHOA mRNA
expression, indicating that aberrant promoter hypermethylation
does not significantly contribute to RHOA silencing in colorectal
cancer. Interestingly, the transcription start site (TSS) of RHOA
is located only three base pairs away from the TSS of TCTA (T-cell
leukaemia translocation altered), a gene that is transcribed in
the opposite direction. The TSSs of both RHOA and TCTA are
contained within the CpG island investigated here and
likely contribute to the regulation of the expression of both
genes. As previous studies have shown that TCTA may have
an oncogenic function, this could explain the absence of
methylation in this CpG island spanning the TSS of RHOA and
TCTA, even in tumours with CpG island methylator phenotype
(CIMP).
Using genome-wide transcriptomic analysis of both mRNA and
miRNA, we identified 12 miRNAs whose expression shows a
significant negative correlation with RHOA mRNA levels, have
putative binding sites in the 30-UTR of RHOA and are significantly
overexpressed in colorectal tumours compared with the normal
colonic mucosa. As expected, some of these miRNAs, including
miR-183 (Bi et al, 2016), miR-20a (Cheng et al, 2016) and miR-185
(Liu et al, 2011), have previously been shown to directly regulate
RHOA levels and/or to be involved in colorectal carcinogenesis.
Here, we further investigated the possible role of miR-200a/b/429
on the regulation of RHOA expression in colorectal cancer
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cells. The miR-200 family is located in two genomic clusters, miR-
200a/b/429 on chromosome 1 and miR200c/141 on chromosome
12. We found that miR-200a/b/429 overexpression significantly
reduced the levels of RHOA expression in LIM2405 colon cancer
cells. These results are in good agreement with a recent report
where miR-200b was found to reduce RHOA expression in
hepatocellular cells (Wong et al, 2015).
Although the function of a protein can be post-transcriptionally
modulated, transcriptional control at the promoter level represents
a major mechanism of gene expression regulation. Here, we
identified a set of 44 transcription factors with evolutionary
conserved binding sites in the promoter of RHOA, whose
expression is significantly correlated with RHOA expression in a
cohort of 244 colorectal tumours, suggesting that they may be
important for the transcriptional regulation of RHOA. Two of
these transcription factors, SMAD4 and c-MYC, are key regulators
of the two most frequently deregulated signalling pathways in
colorectal tumours, TGF-b and Wnt respectively, and we
demonstrate here that they are important for the regulation of
RHOA levels in colon cancer cells.
Inactivation of the TGF-b signalling pathway is important for
colorectal cancer progression, as illustrated by the frequent
alterations observed in TGF-b receptors (Parsons et al, 1995) or
the SMAD intracellular mediators such as SMAD4 inactivation
(Alazzouzi et al, 2005). Although TGF-b signalling has been shown
to activate RHOA in a SMAD-independent manner (Moustakas
et al, 2001), we show here that SMAD4 inactivation leads to a 30–
40% reduction of the levels of RHOA in colon cancer cells,
suggesting that RHOA activation may significantly contribute to
TGF-b-mediated tumour suppression in colonic epithelial cells,
although the specific RHOA-dependent mechanisms remain to be
elucidated. Wnt signalling is a master regulator of proliferation and
differentiation of the normal intestinal epithelium and colon
cancer cells (MacDonald et al, 2009). Aberrant activation of Wnt
signalling in colorectal tumours leads to the accumulation of
nuclear b-catenin that binds to the transcription factor TCF4,
driving the expression of multiple b-catenin/TCF4 target genes,
and c-MYC has been shown to be an important determinant of the
oncogenic effects of Wnt hyperactivation in colorectal tumours
(Sansom et al, 2007). c-MYC positively regulates the expression of
RHOA in glioblastoma, prostate and breast cancer cells as well as
kidney embryonic cells through the direct binding to E-boxes in
the RHOA promoter (Seoane et al, 2002; Si et al, 2010; Talamillo
et al, 2017). Surprisingly, however, we found that in colon cancer
cells SP1 is required for active transcription of RHOA, and that
c-MYC interferes with the binding of SP1 to the RHOA promoter,
thus downregulating RHOA expression, as previously shown for
the CDK inhibitor p21CIP1/WAF1 (Gartel et al, 2001). Therefore, as
we have recently shown that the loss of RHOA enhances Wnt
signalling and significantly contributes to colon cancer progression
and metastasis (Rodrigues et al, 2014), we describe here the
existence of a positive cross-regulatory feedback loop, where
reduced RHOA leads to enhanced Wnt/MYC signalling that in
turn further reduces RHOA levels. Importantly, these data illustrate
how the same transcription factor can regulate in opposite
directions the transcription of the same gene in two different
cancer cell types, highlighting the complexity of gene expression
regulation in the human genome.
In conclusion, we demonstrate a complex pattern of inactivation
of RHOA in colon cancer cells involving overlapping genetic,
transcriptional and post-transcriptional mechanisms in colon cancer
cells. Deletions affecting RHOA are associated with reduced RHOA
expression and miR-200a/b/429 regulates the expression of this
GTPase in colorectal cancer cells. In addition, we demonstrate that
RHOA is regulated by the transcription factors SMAD4 and c-MYC,
key mediators of the most commonly deregulated signalling
pathways on colorectal cancer, TGF-b and Wnt respectively.
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